This post was written by Minyanville contributor Sean Udall.
Aglient Technologies (NYSE: A) just reported this morning and again the company is simply one of the best tech and science shops, which few talk about.
It guided lower but it was minor compared to most tech names of late. Also, A's stock is down about 35% vs. a space down 50% with many names down 65-80% off of highs so the value and durable earnings quality of A is providing some cover.
Circling back to market dynamics, I've contended many times about my view on the markets' four key problems and the difficulty in gaining traction while these are not yet solved. I won't reiterate this whole theme; however, it is noteworthy that we are so willing to spend $350 billion of the TARP while not addressing FAS 157 as well as the uptick rule. Changing these two issues costs the world "nothing". And they are either done with a "pen stroke or a few key strokes".
Yet changing these rules -- might just save the world billions in additional spending, doesn't require Congressional approval, doesn't require the Fed to expand the balance sheet, and lastly doesn't require more rates cuts which could prove quite inflationary.
Last updated: November 14, 2009: 08:27 AM
Hot Stocks
DailyFinance Headlines
- Guru Insight: Jim Stack's naked truth about the current bull market
- Madoff computer programmers arrested; could face 30 years in $60B fraud
- Have stock prices raced ahead of reality? Maybe not
- Jobs for Americans: Which states will take longest to rebound?
- Dow extends two-week winning streak on earnings
Latest from BloggingBuyouts
- Skype soap opera ends as founders set to regain stake ahead of $2B sale
- Big LBOs are teetering, but Wall Street still planning record bonuses
- Cerberus prepares gun company IPO
- Private equity returns down 30% -- and that's the good news
- Private equity fund follows Ayn Rand's teachings and finds opportunity
TheFlyOnTheWall.com Headlines
BioHealth Investor Headlines
- Genzyme Yells All Clear, Sort Of (GENZ)
- Lexicon Punches One Out for IBS (LXRX)
- Oncothyreon (ONTY) Disappoints Investors
- Diabetes Bet Picks Up in MannKind (MNKD)
- Key Biotech Short Interest Changes (AMGN, GILD, BIIB, CELG, GENZ, GERN, LIFE, DNDN, HGSI, AMLN, OSIP)
WalletPop Headlines
- Extreme home makeover, Part III: Falling victim to project creep
- Call of Duty: Retail's silver bullet to boost sales figures
- Green shoots: Clean tech is the fastest growing job market
- $1.6 million raised for St. Jude Children's Research Hospital at 'Taste of New York'
- Faces of loan modification: Mark Bonacorso, Tucson, Ariz.
My Portfolios
Track your stocks here!
Find out why more people track their portfolios on AOL Money & Finance then anywhere else.
BloggingStocks Partners
More from AOL Money & Finance
- Money
- Stock Screener
- Stock Quotes
- Stock Charts
- Banking
- Checking Account
- Savings Account
- Credit Cards
- Credit Report
- DJIA
- Identity Theft
- Debt Management
- Loans
- Auto Loan
- Personal Loans
- Mortgages
- Refinancing
- Taxes
- Retirement
- Insurance
- Small Business
- Earnings
- Dow Jones Industrial Average
- AMT
- Car Insurance
- Common Tax Filing Mistakes
- Credit Score Calculator
- Crude Oil Prices
- DailyFinance
- Deals
- ETF Investing
- Financial Crisis
- GOOG
- Health Insurance
- Historical Stock Prices
- Home Insurance
- Income Tax
- Investing For Retirement
- Life Insurance
- Madoff
- Online Tax Filing
- Pig Flu
- Recession
- Resume Builder
- Stock Brokers
- Stock Ticker
- Tax Advice
- Tax Audit
- Tax Credit
- Tax Deductions
- Tax Forms
- Tech News
WalletPop Headlines
- Extreme home makeover, Part III: Falling victim to project creep
- Call of Duty: Retail's silver bullet to boost sales figures
- Green shoots: Clean tech is the fastest growing job market
- $1.6 million raised for St. Jude Children's Research Hospital at 'Taste of New York'
- Faces of loan modification: Mark Bonacorso, Tucson, Ariz.
Other Weblogs Inc. Network blogs you might be interested in:










